Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Robyn Hunter | F | 62 | 2 years | |
| Rick Bodmer | M | - | 2 years | |
| Robert Sexton | M | - | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Michael Jebsen | M | 52 | 12 years | |
| James M. Weaver | M | 58 | 10 years | |
| Michael Loiacono | M | 58 | 7 years | |
| Roger C. Colman | M | 70 | 5 years | |
| Thomas E. Gardner | M | 76 |
NUCRYST Pharmaceuticals Corp.
 NUCRYST Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activities is to develop, manufacture and commercialize innovative medical products that fight infection and inflammation. | 2 years |
| John E. DeWolf | M | 68 |
Syracuse University
| 6 years |
| Carol L. Amelio | F | 62 |
NUCRYST Pharmaceuticals Corp.
NUCRYST Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activities is to develop, manufacture and commercialize innovative medical products that fight infection and inflammation. | 4 years |
| Dayton Misfeldt | M | 50 | 4 years | |
| Goran Jurkovic | M | 53 | 2 years | |
| Lionel Carnot | M | 56 | 4 years | |
| Mehmet Ömer Arif Aras | M | - |
Syracuse University
| 5 years |
| William C. Mills | M | 68 | 7 years | |
| Illya Keith Maher | M | 56 | 2 years | |
| Joseph M. Landstra | M | 46 | 3 years | |
| Paul J. Schechter | M | 84 |
NUCRYST Pharmaceuticals Corp.
NUCRYST Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activities is to develop, manufacture and commercialize innovative medical products that fight infection and inflammation. | 5 years |
| Catherine R. Ehrenberger | F | 65 | 2 years | |
| Darlene DeRemer | F | 68 |
Syracuse University
| 6 years |
| Bob Cuculich | M | - |
Syracuse University
| 7 years |
| Steven Boyd | M | 43 | 2 years | |
| Thomas R. Curran | M | 65 | 10 years | |
| Lewis Bender | M | 65 | 4 years | |
| Mary Chowning | F | 62 | 5 years | |
| Craig Bell | M | 66 |
Syracuse University
| 5 years |
| Salih Metin Ecevit | M | 78 |
Syracuse University
| 1 years |
| Eric A. Marks | M | - |
Syracuse University
| 4 years |
| Azureen binti Sultan Azlan Shah | F | 67 |
Syracuse University
| 4 years |
| Rick Labs | M | 68 |
Syracuse University
| 4 years |
| Dan Shaffer | M | - |
Syracuse University
| 4 years |
| Wayne Burmaster | M | - |
Syracuse University
| 4 years |
| Stephen Wilklow | M | - |
Syracuse University
| 4 years |
| Wayne Smith | M | 64 |
Syracuse University
| 4 years |
| Agoestiar Zoebier | M | 84 |
Syracuse University
| 2 years |
| Stewart D. Aaron | M | - |
Syracuse University
| 3 years |
| Todd Peter Engelson | M | - |
Syracuse University
| 4 years |
| Greg O'Hara | M | - |
Syracuse University
| 4 years |
| Karl F. Birkenfeld | M | - |
Syracuse University
| 4 years |
| Robert S. Spiess | M | - |
Syracuse University
| 4 years |
| Ruth K Ross | F | - |
Syracuse University
| 4 years |
| Adnan Hasan Eisa Al-Hindi | M | 86 |
Syracuse University
| 3 years |
| Yinglin Mark Xu | M | - |
Bridge Pharmaceuticals, Inc.
 Bridge Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Bridge Laboratories is a preclinical contract research organization (CRO) that provides US-level regulatory-compliant drug development services globally. Bridge is known for its extensive work in toxicology, including vaccines, and safety pharmacology. The company's AAALAC-accredited facility in China was among the first labs to perform GLP studies for clients worldwide. Bridge Laboratories gives drug development clients-biotech/pharmaceutical firms, government agencies and virtual companies with strong outsourcing needs-a CRO choice that can dramatically improve the speed and cost-effectiveness of their drug development research programs. | 4 years |
| Barry Turkanis | M | 70 |
Syracuse University
| 4 years |
| Bob Pochily | M | - |
Syracuse University
| 5 years |
| Bruce Werber | M | 70 |
Syracuse University
| 4 years |
| Abdul Azmin bin Abdul Halim | M | 70 |
Syracuse University
| 4 years |
| Richard Alexander | M | - |
Syracuse University
| 3 years |
| Tre Mischka | M | - |
Syracuse University
| 3 years |
| David Feldman | M | - |
Syracuse University
| 4 years |
| John Romanow | M | - |
Syracuse University
| 4 years |
| Daniel J. Pastuf | M | - |
Syracuse University
| 4 years |
| Paul Brockway Boardman | M | - |
Syracuse University
| 5 years |
| Terry Pigott | M | 67 |
Syracuse University
| 4 years |
| Harris Scott Nydick | M | - |
Syracuse University
| 4 years |
| Ronald Richard Redfield | M | 65 |
Syracuse University
| 3 years |
| Karnaen Anwar Perwataatmadja | M | 84 |
Syracuse University
| 1 years |
| Sharon Barner | F | 67 |
Syracuse University
| 4 years |
| Doug Foulsham | M | - |
Syracuse University
| 4 years |
| Katherine J. Turner | M | 70 |
NUCRYST Pharmaceuticals Corp.
NUCRYST Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activities is to develop, manufacture and commercialize innovative medical products that fight infection and inflammation. | 2 years |
| Michael Terpin | M | 67 |
Syracuse University
| 3 years |
| Michael S. Perlis | M | 71 |
Syracuse University
| 4 years |
| Robert Bruce Kaimowitz | M | - |
Syracuse University
| 5 years |
| Thomas F. Sheehan | M | - |
Syracuse University
| 4 years |
| Eva Fromm O'Brien | F | - |
Syracuse University
| 4 years |
| Cheang Neng Ng | M | 62 |
Syracuse University
| 4 years |
| Robert Becker | M | - |
Syracuse University
| 4 years |
| David M. Walke | M | 69 |
Syracuse University
| 4 years |
| Craig Scholl | M | - |
Syracuse University
| 4 years |
| Marc J. Ostro | M | 74 |
Syracuse University
| 3 years |
| Jeanette H. Quay | F | - |
Syracuse University
| 3 years |
| Edward Pettinella | M | 72 |
Syracuse University
| 2 years |
| Jeffrey Fisher | M | 68 |
Syracuse University
| 4 years |
| John Esposito | M | - |
Syracuse University
| 4 years |
| David John Martinelli | M | 64 |
Syracuse University
| 4 years |
| Carl G. Kleidman | M | 65 |
Syracuse University
| 4 years |
| B. Baldanza | M | 62 |
Syracuse University
| 4 years |
| Glenn S. Armstrong | M | 73 | 3 years | |
| Alex Matturri | M | 66 |
Syracuse University
| 3 years |
| John R. Sanford | M | 60 |
Syracuse University
| 4 years |
| Abdulraouf bin Waleed Al-Baitar | M | 65 |
Syracuse University
| 4 years |
| Mark A. Samuel | M | - |
Syracuse University
| 4 years |
| Andy Feinman | M | - |
Syracuse University
| 4 years |
| Kenneth S. Berryman | M | - |
Syracuse University
| 4 years |
| Ira Winkler | M | - |
Syracuse University
| 5 years |
| R. Earnie Seibert | M | - |
Syracuse University
| 4 years |
| Larry A. Connors | M | - |
Syracuse University
| 4 years |
| Richard J. Caserta | M | - |
Syracuse University
| 4 years |
| Andrew T. Berlin | M | 63 |
Syracuse University
| 4 years |
| Michael Fell | M | - |
Syracuse University
| 2 years |
| James Bertonis | M | - |
Syracuse University
| 4 years |
| Carolyn C. Lindheim | F | - |
Syracuse University
| 4 years |
| Barry Mills | M | 73 |
Syracuse University
| 3 years |
| Mark Shay | M | - |
Syracuse University
| 4 years |
| David C. McDowell | M | 68 |
NUCRYST Pharmaceuticals Corp.
NUCRYST Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activities is to develop, manufacture and commercialize innovative medical products that fight infection and inflammation. | 4 years |
| Rick Ehrlich | M | - |
Syracuse University
| 4 years |
| Michael Brown | M | - |
Syracuse University
| 3 years |
| Tushara Dave | M | - |
Syracuse University
| 1 years |
| Edward Gaj | M | 67 |
NUCRYST Pharmaceuticals Corp.
NUCRYST Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activities is to develop, manufacture and commercialize innovative medical products that fight infection and inflammation. | 3 years |
| Robert Delman | M | - |
Syracuse University
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Eliot Lurier
- Personal Network
